BIVI Biovie Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BIVI

Price (delayed)

$1.37

Market cap

$10.33M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.87

Enterprise value

-$2.47M

?
Relative Growth: Rel. Growth: 22
Relative Strength: Rel. Strength: 19
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 4

BioVie Inc. is developing BIV201 (continuous infusion terlipressin) an Orphan Drug candidate for the treatment of ascites due to advanced liver cirrhosis. First-to-market Orphan therapies typically receive 7 years of ...

Highlights
The EPS has soared by 76% YoY and by 17% from the previous quarter
BIVI's quick ratio is up by 31% from the previous quarter
BIVI's equity is down by 28% year-on-year and by 19% since the previous quarter
The net income is down by 14% since the previous quarter and by 4.9% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.biovieinc.com

Key stats

What are the main financial stats of BIVI

BIVI stock price

How has the Biovie stock price performed over time
Intraday
-4.86%
1 week
-23.89%
1 month
-28.65%
1 year
-81.85%
YTD
18.1%
QTD
-29.38%

Financial performance

How have Biovie's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$20.6M
Net income
-$19.92M
Gross margin
N/A
Net margin
N/A
The net income is down by 14% since the previous quarter and by 4.9% year-on-year
The company's operating income fell by 13% QoQ and by 7% YoY

Price vs fundamentals

How does BIVI's price correlate with its fundamentals

Growth

What is Biovie's growth rate over time

Valuation

What is Biovie stock price valuation
P/E
N/A
P/B
0.66
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 76% YoY and by 17% from the previous quarter
The price to book (P/B) is 89% lower than the 5-year quarterly average of 6.0 and 6% lower than the last 4 quarters average of 0.7
BIVI's equity is down by 28% year-on-year and by 19% since the previous quarter

Efficiency

How efficient is Biovie business performance
BIVI's ROE is down by 23% QoQ
The company's return on assets fell by 23% QoQ and by 13% YoY

Dividends

What is BIVI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BIVI.

Financial health

How did Biovie financials performed over time
BIVI's total liabilities is down by 41% since the previous quarter and by 33% year-on-year
Biovie's current ratio has increased by 38% QoQ and by 7% YoY
BIVI's debt is 98% lower than its equity
BIVI's equity is down by 28% year-on-year and by 19% since the previous quarter
BIVI's debt is down by 19% YoY and by 6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.